Cognitive performance in type 1 diabetes patients is associated with cerebral white matter volume by A. M. Wessels et al.
ARTICLE
Cognitive performance in type 1 diabetes patients
is associated with cerebral white matter volume
A. M. Wessels & S. A. R. B. Rombouts & P. L. Remijnse &
Y. Boom & P. Scheltens & F. Barkhof & R. J. Heine &
F. J. Snoek
Received: 10 January 2007 /Accepted: 23 April 2007 / Published online: 2 June 2007
# Springer-Verlag 2007
Abstract
Aims/hypothesis Cognitive performance in type 1 diabetes
may be compromised as a result of chronic hyperglycaemia.
The aim of this study was to investigate the cognitive
functioning of patients with type 1 diabetes (including a
subgroup with a microvascular complication) and nondia-
betic controls, and to assess the relationship between
cognition and cerebral grey and white matter volumes.
Materials and methods Twenty-five patients with type 1
diabetes (of whom ten had proliferative retinopathy) and
nine nondiabetic controls (matched in terms of sex, age and
education) underwent a neuropsychological examination
and magnetic resonance imaging of the brain. Fractional
brain tissue volumes (tissue volume relative to total
intracranial volume) were obtained from each participant.
Results Compared with nondiabetic controls, patients with
diabetes performed worse on tests measuring speed of
information processing and visuoconstruction; patients with
microvascular disease performed worse on the former
cognitive domain (p=0.03), whereas patients without
complications performed worse on the latter domain
(p=0.01). Patients with a microvascular complication had
a significantly smaller white matter volume than nondiabetic
controls (p=0.04), and smaller white matter volume was
associated with worse performance on the domains of speed
of information processing and attention and executive
function.
Conclusions/interpretation Patients with diabetes demon-
strated several subtle neuropsychological deficits, which
were found to be related to white matter volume. Since
patients with diabetic retinopathy had a smaller white
matter volume, this suggests that cognitive decline is at
least partly mediated by microvascular disease. This needs
to be addressed in future studies.
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Center for Epidemiological Studies Scale for
Depression
DRP diabetic retinopathy
GMF grey matter fraction
MRI magnetic resonance imaging
NDRP no diabetic retinopathy
TI inversion time
TICV total intracranial volume
VBM voxel-based morphometry
WAIS Wechsler adult intelligence scale
WMF white matter fraction
WML white matter lesion
Introduction
Individuals with type 1 diabetes show mild performance
deficits on a range of neuropsychological tests compared
with nondiabetic controls, but the mechanisms underlying
this cognitive deterioration are poorly understood [1].
Retrospective studies in adult patients with type 1 diabetes
have demonstrated an association between a history of
recurrent severe hypoglycaemia and a modest degree of
cognitive impairment [2–7], but large prospective studies
failed to find such an association [8–10].
Two studies have found that of all biomedical variables
examined, clinically significant distal symmetrical polyneu-
ropathy and/or elevated glycosylated haemoglobin values
were most strongly associated with psychomotor slowing
[11, 12]. These findings indicate that diabetes-associated
mental slowing may be associated with hyperglycaemia-
induced complications (particularly retinopathy), resulting
in cerebral microangiopathy. Other evidence for a damag-
ing effect of chronic hyperglycaemia comes from the work
of Ferguson et al. [13]. Subjects with background retinop-
athy performed worse across most cognitive domains
examined. Furthermore, background diabetic retinopathy
(DRP) was associated with small focal white matter
hyperintensities, corresponding to enlarged perivascular
spaces, in the basal ganglia.
Prior studies from our research project also indicate the
existence of an association between retinopathy and
functional and structural changes in the brain [14, 15].
To date, several other studies on structural brain
abnormalities in patients with type 1 diabetes [7, 13, 16–
20] have reported conflicting results concerning the
presence of white matter lesions and cortical atrophy. The
majority of these studies have been based on manual or
semiautomated region-of-interest guided measurements. It
is now well known that whole grey and white matter
volume, as compared with lesion burden, is more closely
related to neuropsychological performance and neuropsy-
chiatric symptoms [21–24]. Measures of tissue atrophy
including whole brain and central atrophy are especially
well correlated with and predictive of cognitive impairment.
Moreover, conventional measures of brain atrophy are more
strongly associated with neuropsychological dysfunction
than measures of lesion burden. White matter atrophy has
been shown to be the best predictor of mental processing
speed and working memory, whereas grey matter atrophy
was associated with verbal memory, euphoria and disinhi-
bition. These results indicate that both grey and white
matter atrophy play a salient role with possible different
functional or behavioural consequences of the disease.
Because abnormal signal intensities from conventional
magnetic resonance imaging (MRI) alone may not enable
prediction of future clinical benefit, increased attention has
been focused on whole brain atrophy, which may indirectly
indicate the total disease burden.
To the best of our knowledge, the relationship between
total brain grey and white matter volume and cognitive
performance in type 1 diabetes has not been studied. The
aim of this study was: (1) to investigate cognitive
functioning in patients with type 1 diabetes and nondiabetic
controls; (2) to determine differences in cognitive perfor-
mance between patients with type 1 diabetes with and
without a microvascular complication (i.e. proliferative
retinopathy); (3) to determine differences in fractional grey
and white matter volumes (tissue volume relative to total
intracranial volume [TICV]) between the groups; and (4) to
establish whether there is an association between cognitive
performance and grey and white matter volume.
Subjects and methods
Participants Twenty-five patients with type 1 diabetes
(WHO, 1999 criteria [25]), of whom ten had a severe
microvascular complication, i.e. diabetic proliferative reti-
nopathy (DRP) (grade 5 DRP according to the EURODIAB
classification [26]), and 15 no diabetic retinopathy (NDRP)
(no microvascular complication, maximum three micro-
aneurysms), and nine nondiabetic controls were included.
Groups were matched for age, sex and education (partici-
pants had to adhere to stringent inclusion criteria to make
sure [beforehand] that the three groups were similar as to
age, sex and level of education) (Table 1).
More detailed information on these participants has been
published previously [14, 15]. All subjects were right
handed and were normotensive (<140/90 mmHg). Four
DRP patients were known to have nephropathy; two other
DRP patients were known to have nephropathy and
neuropathy. Exclusion criteria were previous alcohol or
drug abuse, history of psychiatric disease/treatment, history
1764 Diabetologia (2007) 50:1763–1769
of severe head trauma accompanied by loss of conscious-
ness, stroke, epilepsy, history of severe recurrent hypogly-
caemia (defined as more than five episodes that required
external assistance for recovery) [27], pregnancy and
concomitant diseases that could possibly affect cognitive
function. Written consent was obtained from all subjects
and the protocol was approved by the local medical ethics
review committee. The investigations were carried out in
accordance with the principles of the Declaration of
Helsinki as revised in 2000.
Neuropsychological examination Cognitive functioning of
all subjects was determined by means of a neuropsycho-
logical test battery which focused primarily on attention
and executive functioning and speed of information
processing.
Participants experiencing incipient hypoglycaemia, or
hypoglycaemia in the preceding 24 h, were excluded before
neuropsychological assessment. Evidence of symptomatic
hypoglycaemia or evidence of biochemical hypoglycaemia
or hyperglycaemia (blood glucose <3.5 or >15 mmol/l [28],
respectively) resulted in rescheduling of the neuropsycho-
logical session, since this could affect performance. Blood
glucose values were checked (and adjusted if necessary)
before and during testing using a finger prick.
Thirteen neuropsychological tasks were administered in
a fixed order, which took about 2 h to complete. Each task
was allocated to one of five cognitive domains to reduce
the amount of neuropsychological variables and for
clinical clarity. This division was made a priori, according
to standard neuropsychological practice and cognitive
theory, as described in detail in Lezak et al. [29]. The
domain ‘memory’ consisted of Digit span forward and
backward [30], the 15 Words test [31], the Rey Complex
Figures test, delayed recall condition [32] and the Wechsler
adult intelligence scale (WAIS) Symbol Substitution,
incidental learning test [30]. The domain ‘speed of
information processing’ included the Trail Making Test
Part A [33], the Stroop Colour Word Test (Part I and II)
[34, 35] (28, 29) and the WAIS Symbol Substitution,
coding [30].
The domain ‘attention and executive function’ was
assessed by the Stroop Colour Word Test (Part III) [34,
35], the Trail Making Test Part B [33], the D2 test [36],
GIT sorting [37], the Wisconsin Card Sorting Test [38] and
Wechsler intelligence scale for children Mazes [39]. The
domain ‘fluency’ included the Category Word Fluency task
[40] and the domain ‘visuoconstruction’ was assessed by
the Rey Complex Figures test, copy trial [32] and WAIS
Block Design [30].
As depression is known to have an impact on cognitive
performance [41], and may be associated with white matter
disease [42] we included assessment of depressive symp-
toms with the Dutch version of the Center for Epidemio-
logical Studies Scale for Depression (CES-D) (range 0–60)
[43, 44]. Scores >16 indicate likely depression.
MRI acquisition Imaging was performed on a 1.5 T Siemens
Sonata (Siemens, Erlangen, Germany) scanner using a
standard circularly polarised head coil, with foam padding
to restrict head motion. A localiser scan was first performed
for positioning of the image planes, followed by an
automated shim procedure to improve magnetic field
homogeneity. Scans were obtained as whole brain inversion
time (T1)-weighted magnetisation prepared rapid acquisition
gradient echo volumes and were acquired in the coronal plane
(T1=950 ms, repetition time=2,700 ms; echo time=5.15 ms;
flip angle=8°; 160 slices, voxel size: 1×1×1.5 mm).
MRI data analysis Global brain volumes, calculated from the
T1-weighted images, were analysed using statistical parame
tric mapping (SPM) software (SPM2; Wellcome Department
of Cognitive Neurology, Institute of Neurology, London, UK;
available from http://www.fil.ion.ucl.ac.uk/spm/, last
Table 1 Characteristics of participants
Characteristics NDRPa DRPa Nondiabetic p value
n 15 10 9
Age (years) 42.1±4.5 (34–50) 42.3±5.3 (37–53) 40.9±8.5 (31–52) 0.85
Sex (male:female) 7:8 3:7 3:6 0.66
Level of educationb 5.2±0.9 (3–7) 5.2±1.1 (4–6) 5.7±0.9 (5–7) 0.48
HbA1c (%) 7.8±1.1 (5.3–9.8) 8.0±1.2 (5.4–9.8) NA 0.69
Duration of diabetes (years) 26.4±8.1 (14–37) 32.4±7.6 (23–48) NA 0.08
NA Not applicable
Data are means±SD and range. The p values are for comparison of the three groups by one-way ANOVA (for continuous variables) or the χ2 test
(for binomial variables.
a Two pictures of the retina, one with the macula and one with the optic disc in the centre (using a Topcon non-mydriatic camera) of each eye were
made.
b Education was assessed by a Dutch scoring system [50] that consists of an eight-point scale, ranging from unfinished primary school (level 1) to
university (level 8).
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accessed in May 2007) with the voxel-based morphometry
(VBM) tool Jena script (available from http://dbm.neuro.uni-
jena.de/vbm.html, last accessed in May 2007) in MATLAB
version 6 (The Mathworks, Natick, MA, USA). SPM yielded
whole brain volumetric data, in ml, for three different tissue
types: cerebral spinal fluid, grey matter and white matter.
TICV was defined as the sum of the three tissue types. White
matter fraction (WMF) was defined as white matter volume
divided by TICV and grey matter fraction (GMF) was
defined as grey matter volume divided by TICV.
Statistical analysis Statistical analysis was performed using
SPSS version 11.0 (SPSS, Chicago, IL, USA). Demograph-
ic data of patients and nondiabetic controls were analysed
using a one-way ANOVA (for continuous variables) and by
a χ2 test (for binomial variables).
For each cognitive test, raw scores were converted into
standardised z scores (M=0; SD=1), using the mean and
SD values from the nondiabetic comparison group. Domain
z scores were calculated as the mean z value of the
cognitive tests assigned to that specific domain. Multivar-
iate ANOVA, adjusting for age and level of education and
Bonferroni post hoc comparison, was used to compare
cognitive performance within each domain between the
groups and to study differences in volumetric measures
between the groups. Pearson correlation coefficients were
used to assess the presence of associations between
demographic, clinical, volumetric and neuropsychological
measurements. For the between-group comparisons,
p<0.05 was considered statistically significant.
Results
Cognitive performance There was a significant difference
(after adjusting for age and education) on cognitive perfor-
mance between the groups on the domain of speed of
information processing (p=0.024) and the domain of
visuoconstruction (p=0.035). Contrasts revealed that, on
the domain of speed of information processing, DRP patients
performed worse compared with the control group
(p=0.025; effect size 0.5). No significant differences were
observed between the DRP and the NDRP group and
between the NDRP group and the nondiabetic controls on
this domain. On the domain of visuoconstruction, it appeared
that NDRP patients performed worse as compared with the
nondiabetic reference group (p=0.031; effect size 0.4).
The NDRP group as well as the DRP group reported
significantly more depressive symptoms (NDRP: 12.4±8.9
and DRP: 13.0±10.8) than nondiabetic controls (3.2±3.8)
(both: p=0.02). Six patients (three DRP and three NDRP
patients) and no nondiabetic controls scored above the
criterion score of 16 for the depression scale (Table 2).
Rerunning the analysis with adjustment for the depression
score did not change the aforementioned results.
Brain measurements There was a significant difference in
WMF between the groups (p=0.035). Contrasts revealed
that DRP patients displayed significantly decreased WMF
compared with the nondiabetic controls (p=0.035; effect
size 0.4). No differences in WMF were observed between
the NDRP group and the nondiabetic control group and the
NDRP and the DRP group. Furthermore, no significant
differences between the three groups in GMF were
observed (Table 3). The results did not change when we
adjusted for sex.
The relationship between demographics, clinical variables,
volumetric measurements and neuropsychological perfor-
mance was tested using Pearson correlation coefficients
(Table 4). White matter volume was positively correlated
with performance on the domain of speed of information
processing and attention and executive functioning. No
correlation was found between grey matter volume and
neuropsychological performance.
Table 2 Cognitive performance
Domain NDRP DRP Nondiabetic
n 15 10 9
Memory −0.22±0.17 −0.37±0.21 0±0.24
Speed of information processing −1.12±0.22 −1.41±0.26 −0.26±0.30a
Attention and executive functioning −0.32±0.10 −0.06±0.13 −0.05±0.14
Fluency −0.25±0.20 −0.44±0.25 0.06±0.28
Visuoconstruction −0.96±0.19 −0.61±0.23 −0.05±0.26b
Domain scores are z scores±SE evaluated at covariates in the model: age and education and adjusted for multiple comparisons (Bonferroni)
a p<0.05 for DRP vs nondiabetic
b p<0.05 for NDRP vs nondiabetic
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Discussion
The results of this study suggest that cognitive performance
in relatively young diabetic patients is worse with regard to
tests measuring speed of information processing and visuo-
construction as compared with sex-, age- and education-
matched nondiabetic controls. Notably, patients with a
microvascular complication showed a decreased white matter
volume compared with nondiabetic controls. Reduced white
matter volume was associated with worse performance in the
domain of speed of information processing and attention and
executive functioning.
Our findings are in line with the literature suggesting
that deficits in speed of information processing and
cognitive slowing are the fundamental features of clinical
disorders characterised by abnormalities in cerebral white
matter [45]. For example Sanfilipo et al. [21] found in
patients with multiple sclerosis that white matter atrophy
was the best predictor of mental processing speed and
working memory. Dow et al. [46] also suggested a
relationship between reduced white matter volume and
impaired processing speed performance in patients with
temporal lobe epilepsy.
Evidence is increasing that psychomotor slowing is a
core cognitive deficit associated with diabetes [47], and
studies have demonstrated that the presence of microvas-
cular complications like retinopathy is predictive of mental
slowing in adults with type 1 diabetes [12, 13]. Further-
more, retinal microvascular abnormalities have been shown
to relate to white matter lesions (WMLs) in a population of
patients with type 1 diabetes [13] and healthy middle-aged
men and women [48]. In this study, we focused on whole
grey and white matter volume, as compared with lesion
burden, because evidence suggests these are more closely
related to neuropsychological performance [21–24]. We
found a relationship between white matter atrophy and
Table 3 GMF and WMF measurements
Measurements NDRP DRP Nondiabetic p value
n 15 10 9
GMF 0.444±0.005 0.430±0.006 0.434±0.006 0.18
WMF 0.273±0.004 0.266±0.005 0.286±0.005 0.04
Data are means±SE evaluated with age as a covariate in the model and adjusted for multiple comparisons (Bonferroni). The p values are for
comparison of the three groups by one-way ANOVA
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performance in the domain of speed of information
processing and attention and executive function. These
results are consistent with the notion that temporary storage
and manipulation of new information may require rapid
communication between different brain regions via white
matter tracts, which may become compromised with progres-
sion of the disease. This finding indirectly suggests that
disruption of centrally located cortical subcortical white matter
connections may be responsible for slower processing speed.
In an earlier study, we did demonstrate modest focal
cortical grey matter atrophy in patients with a microvascu-
lar complication using VBM [15]. VBM is a fully
automated whole brain technique that detects regionally
specific differences in brain tissue composition on a voxel-
by-voxel basis. At its simplest, it involves a voxel-wise
comparison of the local concentration of grey matter
between groups of subjects [49]. In fact, regional differ-
ences in grey matter density are estimated, whereas in the
present study we assessed differences in whole brain
volume, i.e. a different approach. Apparently, in this
particular sample, focally significant differences in grey
matter when analysing grey matter differences voxel-wise,
are not reflected in whole brain grey matter volume
differences, probably because of more noise in the latter
technique.
Whether type 1 diabetes is indeed characterised by changes
in cerebral white matter or whether diabetes can be charac-
terised by global brain atrophy (affecting both grey and white
matter) needs to be clarified in future longitudinal studies.
Limitations of this study are its small sample size (our
results should therefore be interpreted with caution) and its
cross-sectional design, which does not yield information on
the temporal relationship between deficits in white matter
volume and cognitive performance. Moreover, we cannot
discern whether the smaller white matter volumes are due
to loss of normal-appearing white matter or to decreased
maturation of white matter. Because we did not use an MRI
technique to determine WMLs, the relationship between
white matter volume loss, WMLs and cognitive perfor-
mance could not be explored in the current study.
Furthermore, the use of whole brain grey and white matter
volumes also precluded any definitive discussion regarding
the localisation of brain cognition relationships.
A strength of our study is the inclusion of a nondiabetic
control group, matched (on group level) for sex, age and
education (although a 1:1 matching would have even been
better). This allowed us to investigate the effect of diabetes
per se on cognitive performance and on brain measure-
ments. It also enabled us to assess the effect of microvas-
cular disease (i.e. proliferative retinopathy) on these
measurements, and link cognitive performance with brain
measurements. Our results did not support (or refute) the
hypothesis that reduced cognitive performance is associated
with the presence of microvascular disease. The differences
found are likely to be associated with diabetes per se,
independently of disease status. However, the subtle
deficits found were specifically related to white matter
volume. Since persons with DRP had a smaller white
matter volume; this suggests that cognitive decline is at
least partly mediated by microvascular disease. This
hypothesis needs to be addressed in future studies. Future
longitudinal studies should also utilise newer MRI techni-
ques, such as diffusion tensor imaging, to quantify changes
in the integrity of the cerebral white matter and to enhance
our understanding of the potential mechanisms underlying
structural brain damage and its effect on cognitive
performance in patients with type 1 diabetes.
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